



## ***Genetic Analysis: Development project initiated for a new companion diagnostic test***

**OSLO, NORWAY – 12 October 2023:** Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed a pilot project and initiated a development project in collaboration with a global pharmaceutical company to develop a new microbiome-based rapid companion\* diagnostic PCR test. The development project’s goal is to provide clinicians with a decision tool for prescribing treatment and monitoring treatment effects aimed at faster clinical decision-making.

A new microbiome diagnostic test providing rapid testing in human microbiomes is the goal as GA initiates a new development project with a leading global pharmaceutical company. The project aims to provide increased standardization and potentially faster clinical decision-making at a low cost by developing GA’s proprietary technology diagnostics platform GA-map® for use in a simple microbiome-based rapid PCR test. The collaboration partner is a leading pharmaceutical company with a high focus on gastroenterology. By combining the research and technology of the two companies into a simple microbiome-based rapid PCR test, clinicians will have a tool enabling patient stratification for treatment prescription and monitoring treatment effect.

**Ronny Hermansen, CEO of Genetic Analysis, comments:**

*“We are thrilled to announce our development project for a new microbiome-based rapid PCR test – driving vital change in microbiome diagnostics. This validates our strategy to become the preferred partner for pharmaceutical companies who want to co-develop tests tailor-made for their pharma products. The next step will also focus on further exploring the commercial possibilities of a new microbiome-based rapid diagnostic PCR test. I look forward to keeping our investors updated as the project proceeds.”*

\*A companion diagnostic is here to be understood as an in vitro diagnostic (IVD), which provides information for the effective use of a corresponding drug or biological product.

**For more information, please contact:**

Ronny Hermansen, CEO  
E-mail: [rh@genetic-analysis.com](mailto:rh@genetic-analysis.com)

**About Genetic Analysis:**

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more general information: [www.genetic-analysis.com](http://www.genetic-analysis.com)

Stay updated on GA and sign up for more investor-related information: <https://www.genetic-analysis.com/subscriptions/>

Interested in reading more about GA’s products? Please visit [ga-map.com](http://ga-map.com)